Proteo® Super early detection of cancer
PROTEO
With early detection, the 5-year survival rate is over 95%!
Did you know? We are now in an age where most cancers that are detected early can be cured.
It is generally said that a patient is cured if there is no recurrence for five years after treatment has ended. However, looking at the data published by the National Cancer Center Council*1,
<For those who have had cancer discovered at stage I and undergone surgery>
The 5-year relative survival rate has been announced to be 95.4% for all cancers, and 100% for stomach cancer, rectal cancer, breast cancer, etc.
However, if detection is delayed and the cancer progresses to stage IV, the five-year relative survival rate drops significantly, to 16.9% for stomach cancer, for example. The
most important thing in cancer treatment is to detect cancer early. This
applies to solid cancers such as lung cancer, breast cancer, stomach cancer, liver cancer, colon cancer, tongue cancer, thyroid cancer, kidney cancer, prostate cancer, uterine cancer, and ovarian cancer.
Joint Survival Rate Survey of Facilities Affiliated with the National Cancer Association )
When cancer develops in the body, cancer-related substances are released into the blood. Cancer-related substances in the blood adsorbed to the test chip are measured using a fluorescence microscope, and the risk of cancer is determined in three stages, A, B, and C.
The test requires only a very small amount of blood, just 30 microliters, and is not affected by food or other factors.
Another feature of this test is that the measured values show clear differences. In addition to early detection of cancer, this test is also useful for determining the risk of progression, recurrence, metastasis, and treatment effectiveness.
Cancer-related substances: Protein complexes containing DNA (presumed nucleosomes) react with and are adsorbed by silver peroxide mesocrystals, a new substance formed on the ProteoⓇ chip. By looking at this with a fluorescence microscope, it is possible to detect even very early stage cancers, making it possible to identify and examine multiple cancers in a single examination.
It is very difficult to distinguish between benign and malignant tumors, and highly sensitive and highly specific testing methods are required.
Because crystals of free cancer-related substances in the blood are derived from cells related to apoptosis, they are found in small amounts in benign diseases (people who do not have cancer) and benign tumors, but are found in particularly large amounts in cancer.
Compared to benign diseases and benign tumors, more fluorescence is seen in malignant tumors.
Inspection amount
Collection fee + examination fee: 200,000 yen (tax included)
*This treatment is an elective medical treatment.
Inspection flow
1. A small amount of blood is taken from the fingertip or other area.
2. The blood is sent to a specialized testing facility for testing. The results of the Proteo® test are quantified and risk assessment is performed, and a test report is sent to your doctor.
3. Your doctor will explain the results based on the test report. Depending on the results, we may recommend additional tests or provide suggestions for future treatment.
Q&A
Do I need to refrain from eating or drinking before blood collection?
Tests with ProteoⓇ are not affected by food or drink, so there is no need for dietary restrictions. However, please refrain from excessive alcohol intake.
Can I use health insurance?
Health insurance is not applicable because it is treated as a free medical treatment.
